// App-Quantinova.ai

16374 : Effect of Dapagliflozin According to Duration of Heart Failure: An Analysis of the DAPA-HF Trial

Researchers

Presenter

  • Su E Yeoh

Principal Investigators

  • Kieran Docherty

  • Silvio E Inzucchi

  • Lars Kober

  • Mikhail Kosiborod

  • Anna Maria Langkilde

  • Feilpe A Martinez

  • Olof Bengtsson

  • Piotr Ponikowski

  • Marc S Sabatine

  • Mikaela Sjostrand

  • Scott Solomon

  • Pardeep S Jhund

  • John J McMurray

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • Univ of Glasgow, Glasgow

  • Rigshospitalet, Copenhagen, Denmark

  • Saint Lukes Mid America Heart Institute, Kansas City, MO

  • ASTRAZENECA, M Lndal, Sweden

  • National Univ of Cordoba, Cordoba, Argentina

  • AstraZeneca, Molndal, Sweden

  • Wroclaw Med U, Wroclaw, Poland

  • TIMI Study Group, Boston, MA

  • Brigham & Women's Hospital, Boston, MA

  • UNIVERSITY OF GLASGOW, Glasgow

  • BHF CARDIOVASCULAR RESEARCH CENTRE, Glasgow

Locations

  • United Kingdom

  • United States

  • Denmark

  • Sweden

  • Argentina

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Congestive heart failure

Biomarkers

  • N/A

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved